The Shared Investigator Platform (SIP) is a single information technology solution that facilitates investigative site collaboration with multiple clinical trial sponsors. The SIP reduces the time it takes to initiate a trial by relieving administrative burden and simplifies, accelerates, and reimagines the site and sponsor relationship.
In early 2019, AACI formed a task force of AACI cancer center members to discuss and identify the challenges of SIP implementation. Through collaboration with Cognizant and industry sponsors, the task force helps trial sites setting up their SIP profiles and suggests ways for AACI cancer centers to establish relationships with each other, Cognizant, and sponsors.
Chair - Theresa L. Werner, MD
CTO Medical Director
Huntsman Cancer Institute, University of Utah
View All Task Force Members
On May 28, 2020, Cognizant hosted a webinar sharing a high-level overview of the SIP, including a demonstration on how the SIP works, facility set-up examples, and updates.
In order to best serve AACI's members, Cognizant created a "divide-and-conquer" solution to pair each cancer center with a SIP Champion Sponsor. These dedicated sponsors are trained to help create organizational and departmental profiles, upload CVs, and answer general questions related to the implementation process.
On June 18, AACI's Clinical Research Innovation (CRI) hosted a webinar titled "Implementing the Shared Investigator Platform." Panelists were Hobs Apell, The University of Kansas Cancer Center; Lindsay Casetta, CCRP, Barbara Ann Karmanos Cancer Institute; Jessica Moehle, CCRP, Huntsman Cancer Institute; Lestter Cruz, MD, Cognizant; and Kendra Todd, MBA, OHSU Knight Cancer Institute.
ICYMI: Read Our Recap
AACI and Cognizant will continue to facilitate webinars to relay best practices and new information to centers at various stages of the SIP implementation process.
These materials have not been published and are not available to the general public because they are proprietary to Cognizant and contain Cognizant confidential and/or trade secret information, including without limitation the descriptions of features, functions, methods, techniques, and technical concepts contained herein. These materials may also contain information covered by U.S. and/or foreign patents or patent applications. Use, distribution or copying of these materials, in whole or in part, is forbidden, except with Cognizant’s express prior written permission.
The documentation is provided “as is” and all express or implied conditions, representations and warranties, including any implied warranty of merchantability, fitness for a particular purpose or non-infringement, are disclaimed, except to the extent that such disclaimers are held to be legally invalid. Cognizant shall not be liable for any incidental or consequential damages in connection with the furnishing, performance, or use of this documentation. The information contained in this documentation is subject to change without notice.
Cognizant® and Shared Investigator Platform are either registered trademarks or trademarks of Cognizant in the United States and other countries. Other trademarks referenced herein are the property of their respective owners.